Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of ...

Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.

Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...

Creative Biolabs’ expanded primary neuron portfolio includes cortical, hippocampal, dopaminergic, and sensory neurons isolated and characterized under stringent quality control (QC) standards and ...

Apellis Pharmaceuticals (NASDAQ:APLS) used its fourth-quarter and full-year 2025 earnings call to highlight what management ...

A team of researchers have come to the conclusion that cities are warming much faster than the surrounding countryside, the ...

Apellis Pharmaceuticals APLS reported fourth-quarter 2025 loss of 47 cents per share, wider than the Zacks Consensus Estimate of a loss of 39 cents. The company had incurred a loss of 29 cents in ...

Climate and Earth system modelling is the use of mathematical representations of key components and properties of the atmosphere, ocean and biosphere to construct computer models. These models – which ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, ...